(PODD) Insulet - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 14.326m USD | Total Return: -17.6% in 12m

Insulin Pumps, Diabetes Management, Drug Delivery
Total Rating 44
Safety 83
Buy Signal -0.52
Medical Devices
Industry Rotation: -4.7
Market Cap: 14.3B
Avg Turnover: 195M USD
ATR: 3.89%
Peers RS (IBD): 15.7
Risk 5d forecast
Volatility36.0%
Rel. Tail Risk-8.44%
Reward TTM
Sharpe Ratio-0.52
Alpha-46.09
Character TTM
Beta0.799
Beta Downside1.105
Drawdowns 3y
Max DD61.31%
CAGR/Max DD-0.22
EPS (Earnings per Share) EPS (Earnings per Share) of PODD over the last years for every Quarter: "2021-03": 0, "2021-06": 0.23, "2021-09": 0.18, "2021-12": 0.42, "2022-03": 0.4, "2022-06": -0.5, "2022-09": 0.35, "2022-12": 0.24, "2023-03": 0.23, "2023-06": 0.38, "2023-09": 0.71, "2023-12": 1.4, "2024-03": 0.73, "2024-06": 0.55, "2024-09": 0.9, "2024-12": 1.15, "2025-03": 1.02, "2025-06": 1.17, "2025-09": 1.24, "2025-12": 1.44, "2026-03": 0,
EPS CAGR: 73.79%
EPS Trend: 57.5%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of PODD over the last years for every Quarter: 2021-03: 252.3, 2021-06: 263.2, 2021-09: 275.6, 2021-12: 307.7, 2022-03: 295.4, 2022-06: 299.4, 2022-09: 340.8, 2022-12: 369.7, 2023-03: 358.1, 2023-06: 396.5, 2023-09: 432.7, 2023-12: 509.8, 2024-03: 441.7, 2024-06: 488.5, 2024-09: 543.9, 2024-12: 597.5, 2025-03: 569, 2025-06: 649.1, 2025-09: 706.3, 2025-12: 783.8, 2026-03: null,
Rev. CAGR: 29.72%
Rev. Trend: 98.5%
Last SUE: 1.58
Qual. Beats: 16

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: PODD Insulet

Insulet Corporation specializes in the development and manufacture of tubeless insulin delivery systems, primarily through its Omnipod product line. Its flagship offerings include the Omnipod 5, an automated insulin delivery system that integrates with continuous glucose monitors via Bluetooth, and the Omnipod DASH system. Beyond diabetes care, the company adapts its wearable technology for non-insulin drug delivery, such as the Neulasta Onpro kit used in oncology.

The company operates within the medical device sector, utilizing a recurring revenue business model driven by the continuous need for disposable pods. Unlike traditional durable insulin pumps that require multi-year commitments, Insulet frequently distributes its products through the pharmacy channel, lowering the initial cost barrier for patients and increasing market accessibility. For a deeper look into the companys valuation metrics, you may want to explore ValueRay.

Headquartered in Acton, Massachusetts, Insulet maintains a global presence, selling to end-users both directly and through independent distributors. This dual focus on automated glucose management and strategic pharmaceutical partnerships positions the firm as a key player in the evolving landscape of wearable healthcare technology.

Headlines to Watch Out For
  • Omnipod 5 adoption drives revenue growth
  • Competition intensifies in automated insulin delivery market
  • Regulatory approvals impact product launch timelines
  • Reimbursement policies affect patient access and sales
  • Manufacturing costs influence profit margins
Piotroski VR‑10 (Strict) 9.0
Net Income: 247.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.40 > 1.0
NWC/Revenue: 44.63% < 20% (prev 64.82%; Δ -20.19% < -1%)
CFO/TA 0.18 > 3% & CFO 569.3m > Net Income 247.1m
Net Debt (334.7m) to EBITDA (486.6m): 0.69 < 3
Current Ratio: 2.78 > 1.5 & < 3
Outstanding Shares: last quarter (70.7m) vs 12m ago -4.61% < -2%
Gross Margin: 71.63% > 18% (prev 0.70%; Δ 7.09k% > 0.5%)
Asset Turnover: 86.27% > 50% (prev 67.09%; Δ 19.18% > 0%)
Interest Coverage Ratio: 6.09 > 6 (EBITDA TTM 486.6m / Interest Expense TTM 64.0m)
Altman Z'' 3.80
A: 0.38 (Total Current Assets 1.89b - Total Current Liabilities 680.1m) / Total Assets 3.19b
B: 0.09 (Retained Earnings 287.4m / Total Assets 3.19b)
C: 0.12 (EBIT TTM 390.0m / Avg Total Assets 3.14b)
D: 0.18 (Book Value of Equity 300.7m / Total Liabilities 1.68b)
Altman-Z'' Score: 3.80 = AA
Beneish M -2.91
DSRI: 1.08 (Receivables 516.9m/365.5m, Revenue 2.71b/2.07b)
GMI: 0.97 (GM 71.63% / 69.79%)
AQI: 0.93 (AQ_t 0.14 / AQ_t-1 0.15)
SGI: 1.31 (Revenue 2.71b / 2.07b)
TATA: -0.10 (NI 247.1m - CFO 569.3m) / TA 3.19b)
Beneish M-Score: -2.91 (Cap -4..+1) = A
What is the price of PODD shares? As of April 09, 2026, the stock is trading at USD 203.51 with a total of 687,303 shares traded.
Over the past week, the price has changed by -1.70%, over one month by -15.34%, over three months by -30.52% and over the past year by -17.62%.
Is PODD a buy, sell or hold? Insulet has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy PODD.
  • StrongBuy: 14
  • Buy: 6
  • Hold: 2
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the PODD price?
Analysts Target Price 351.4 72.7%
Insulet (PODD) - Fundamental Data Overview as of 08 April 2026
P/E Trailing = 58.6455
P/E Forward = 32.6797
P/S = 5.2899
P/B = 9.4944
P/EG = 1.4266
Revenue TTM = 2.71b USD
EBIT TTM = 390.0m USD
EBITDA TTM = 486.6m USD
Long Term Debt = 930.8m USD (from longTermDebt, last quarter)
Short Term Debt = 22.2m USD (from shortTermDebt, last quarter)
Debt = 1.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 334.7m USD (from netDebt column, last quarter)
Enterprise Value = 14.66b USD (14.33b + Debt 1.05b - CCE 716.1m)
Interest Coverage Ratio = 6.09 (Ebit TTM 390.0m / Interest Expense TTM 64.0m)
EV/FCF = 38.81x (Enterprise Value 14.66b / FCF TTM 377.7m)
FCF Yield = 2.58% (FCF TTM 377.7m / Enterprise Value 14.66b)
FCF Margin = 13.95% (FCF TTM 377.7m / Revenue TTM 2.71b)
Net Margin = 9.12% (Net Income TTM 247.1m / Revenue TTM 2.71b)
Gross Margin = 71.63% ((Revenue TTM 2.71b - Cost of Revenue TTM 768.3m) / Revenue TTM)
Gross Margin QoQ = 72.54% (prev 72.22%)
Tobins Q-Ratio = 4.60 (Enterprise Value 14.66b / Total Assets 3.19b)
Interest Expense / Debt = 1.87% (Interest Expense 19.6m / Debt 1.05b)
Taxrate = 27.46% (38.5m / 140.2m)
NOPAT = 282.9m (EBIT 390.0m * (1 - 27.46%))
Current Ratio = 2.78 (Total Current Assets 1.89b / Total Current Liabilities 680.1m)
Debt / Equity = 0.69 (Debt 1.05b / totalStockholderEquity, last quarter 1.52b)
Debt / EBITDA = 0.69 (Net Debt 334.7m / EBITDA 486.6m)
Debt / FCF = 0.89 (Net Debt 334.7m / FCF TTM 377.7m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.87% (Net Income 247.1m / Total Assets 3.19b)
RoE = 17.36% (Net Income TTM 247.1m / Total Stockholder Equity 1.42b)
RoCE = 16.57% (EBIT 390.0m / Capital Employed (Equity 1.42b + L.T.Debt 930.8m))
RoIC = 10.52% (NOPAT 282.9m / Invested Capital 2.69b)
WACC = 8.28% (E(14.33b)/V(15.38b) * Re(8.79%) + D(1.05b)/V(15.38b) * Rd(1.87%) * (1-Tc(0.27)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.58%
[DCF] Terminal Value 69.40% ; FCFF base≈343.2m ; Y1≈225.3m ; Y5≈103.0m
[DCF] Fair Price = 22.88 (EV 1.95b - Net Debt 334.7m = Equity 1.61b / Shares 70.4m; r=8.28% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 57.53 | EPS CAGR: 73.79% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 29.72% | SUE: 1.58 | # QB: 16
EPS next Quarter (2026-06-30): EPS=1.44 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=+4 | Analysts=20
EPS current Year (2026-12-31): EPS=6.35 | Chg7d=+0.000 | Chg30d=-0.000 | Revisions Net=+18 | Growth EPS=+27.7% | Growth Revenue=+22.0%
EPS next Year (2027-12-31): EPS=8.08 | Chg7d=+0.000 | Chg30d=-0.006 | Revisions Net=+18 | Growth EPS=+27.3% | Growth Revenue=+19.2%
[Analyst] Revisions Ratio: +0.22 (11 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.1% (Discount Rate 8.8% - Earnings Yield 1.7%)
[Growth] Growth Spread = +14.5% (Analyst 21.6% - Implied 7.1%)
External Resources
Dataroma Stockcircle